SCHEMBL6736902

SCHEMBL6736902

CCOC(=O)C(Cc1ccc(OCCC/C=C2/c3ccccc3COc3ccccc32)cc1)OC

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 0.71
PPARA Q07869 4/20 0.71
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
RECQL P46063 1/20 0.45
PMP22 Q01453 1/20 0.45
HRH1 P35367 4/20 0.44
KCNH2 Q12809 2/20 0.44
HTR2B P41595 2/20 0.44
LMNA P02545 2/20 0.44
SLC22A1 O15245 1/20 0.44
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
HTR1A P08908 1/20 0.44
CHRM5 P08912 1/20 0.44
ADRA2A P08913 1/20 0.44
CHRM1 P11229 1/20 0.44
DRD2 P14416 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6736904 1.00 PPARG (0.71) PPARGPPARAALDH1A1KDM4ERECQL
SCHEMBL6740656 0.96 PPARG (0.77) PPARGPPARAALDH1A1KDM4ERECQL
SCHEMBL6740655 0.96 PPARG (0.77) PPARGPPARAALDH1A1KDM4ERECQL
SCHEMBL6740446 0.93 PPARG (0.79) PPARGPPARAALDH1A1KDM4ERECQL
SCHEMBL6740449 0.93 PPARG (0.79) PPARGPPARAALDH1A1KDM4ERECQL
SCHEMBL6737472 0.92 PPARG (0.61) PPARGPPARAPPARD
SCHEMBL6730961 0.91 PPARG (0.72) PPARGPPARAALDH1A1KDM4ERECQL
SCHEMBL6730960 0.91 PPARG (0.72) PPARGPPARAALDH1A1KDM4ERECQL
SCHEMBL6735627 0.91 PPARG (0.79) PPARGPPARAALDH1A1KDM4ERECQL
SCHEMBL6739237 0.91 PPARG (0.63) PPARGPPARAALDH1A1KDM4ERECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020115654-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-08-22 US claimed
US-6683111-B2 SUCH AS 2-ETHOXY-3-(4-(2-XANTHEN-9-YLIDENE-ETHOXY)-PHENYL)-PROPIONIC ACID; FOR TREATING CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TREATMENT OF DIABETES/OBESITY NOVO NORDISK A/S (DK) 2004-01-27 US disclosed
US-20020115654-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-08-22 US disclosed
US-6353018-B1 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2002-03-05 US disclosed
EP-1123267-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP disclosed
WO-2000023415-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115654-A1 New compounds, their preparation and use PPARG, PPARD, PPARA PPARG 1/4885PPARA 3/4885ALDH1A1 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.